FTO protects human granulosa cells from chemotherapy-induced cytotoxicity

Rongli Wang¹, Wei Wang², Lijun Wang¹, Linnan Yuan¹, Feiyan Cheng¹, Xin Guan¹, Nini Zheng¹ and Xinyuan Yang¹*

Abstract

Background: Premature ovarian failure (POF) is a serious problem for young women who receive chemotherapy, and its pathophysiological basis is the dysfunction of granulosa cells. According to previous reports, menstrual-derived stem cells (MenSCs) can restore ovarian function and folliculogenesis in mice with chemotherapy-induced POF. Fat mass- and obesity-associated (FTO) was reported to be associated with oocyte development and maturation. FTO was decreased in POF and may be a biomarker for the occurrence of POF. Knockdown of FTO in granulosa cells promoted cell apoptosis and inhibited proliferation. But the relationship between FTO and ovarian repair was still unclear. This study was aimed at investigating the FTO expression level and the role of FTO in the MenSCs recovering the function of injured granulosa cells.

Method: First, cisplatin was used to establish a granulosa cell injury model. Then, the MenSCs and injured granulosa cell coculture model and POF mouse model were established in this study to explore the role of FTO. Furthermore, gain- and loss-of-function studies, small interfering RNA transfection, and meclofenamic acid (MA), a highly selective inhibitor of FTO, studies were also conducted to clarify the regulatory mechanism of FTO in granulosa cells.

Results: MenSCs coculture could improve the function of injured granulosa cells by increasing the expression of FTO. MenSCs transplantation restored the expression of FTO in the ovaries of POF mice. Overexpression of FTO restored the injured cell proliferation and decreased apoptosis by regulating the expression of BNIP3. Down-regulation of FTO got the opposite results.

Conclusions: In the treatment of MenSCs, FTO has a protective effect, which could improve the viability of granulosa cells after cisplatin treatment by decreasing the expression of BNIP3. Meanwhile, FTO may provide new insight into therapeutic targets for the chemotherapy-induced POF.

Keywords: FTO, POF, Menstrual-derived stem cells, BNIP3

Background

Premature ovarian failure (POF) is prevalent in 1–3% of women under 40 years old, and its features include the disordered ovarian function, the elevated gonadotropin hormone, and descended estrogen levels. There are many potential causes for this disease involving genes, autoimmunity, and iatrogenicity [1]. The most important and common causes of POF are chemotherapy [2]. Various studies have indicated that chemotherapy could cause small follicle depletion and even exhaustion of oocytes in the ovaries of young females with cancer, leading to POF [3, 4]. Cisplatin (Cis-diamminedichloroplatinum-II (CDDP)) is a widely used and effective chemotherapeutic agent for the treatment of cancers, including gynecologic malignancies [5, 6]. However, when used at higher dosages, injury may occur, such as nephrotoxicity [6], ototoxicity [7], and reproductive toxicity [2, 8, 9]. Previous
studies reported that cisplatin caused POF during clinical usage [8, 9] and non-clinical investigation [10], and exposure of granulosa cells to cisplatin caused growth arrest, DNA damage, and increased apoptosis [11]. Therefore, the preservation of fertility and gonadal function has become an important issue for patients receiving chemotherapy of reproductive age. To overcome these side effects, many studies have been performed, and protective adjuvants have been developed [12, 13]. In particular, the therapeutic potential of stem cells attracted increasing attention [14–16]. Animal experiments have indicated that transplantation mesenchymal stem cell (MSC) can partially ameliorate the structure and function of injured ovaries [17, 18]. In POF mouse/rat models, intravaginal or intravenous injection of MenSCs reduced apoptosis and restored ovarian function [14, 16, 19]. Dilabeled MenSCs were demonstrated to localize to granulosa cells of immature follicles [16]. Moreover, a recent clinical trial indicated that in poor ovarian responders, autologous MenSCs intraovarian injection could increase clinical pregnancy and live births rates [20]. Our previous study also indicated that MenSCs have reparative effects on cisplatin-induced premature ovarian failure mice. MenSCs transplantation reduced ovarian interstitium fibrosis and apoptosis of granulosa cells [3]. However, the regulation mechanism is still unknown.

RNA methylation on the sixth N atom of adenylic (m6A), one of the most abundant modifications on RNA, has captured the attention of researchers [21]. m6A can regulate gene expression in many physiological processes, and abnormal m6A modifications may lead to dysfunctions of RNA, which can further trigger diseases such as oocyte development disorders [22], metabolic diseases [23], and cancers [24]. m6A is a series of proteins composed of m6A methyltransferase (writers), m6A demethylases (erasers), and m6A-binding proteins (readers) [25]. They can add, remove, and recognize the m6A-modified site, which indicates that m6A RNA methylation is reversible and dynamic. It can be catalyzed by “Writers” and be erased by “Erasers”. “Writers” are a complex that consists of METTL3, METTL14, RNA binding motif protein 15 (RBM15), Wilms’ tumor 1-associating protein (WTAP), zinc finger CCCH domain-containing protein 13 (ZC3H13), vir like m6A methyltransferase associated protein (KIAA1429), and others, and involves in oocyte maturation [26, 27]. “Readers” are a series of YTH domain-containing proteins, such as YTHDF1, YTHDF2, YTHDF3, and YTHDC1 [28, 29], that are essential for early zygotic development and oocyte competence. YTHDF2 knockout mice are infertile and compared with littermates, YTHDF2 knockout mice have significantly smaller testes [30]. “Erasers” are consist of FTO (fat mass- and obesity-associated) and α-ketoglutarate-dependent dioxygenase AlkB homolog 5 (ALKBH5). FTO catalyzes the demethylation of m6A and causes multiple malformations and growth retardation in loss-of-function mutation [31]. In male germ cells, down-regulation of FTO suppresses spermatogonial proliferation [28]. During female oocyte development, the levels of RNA methylation are decreased [32]. The most recent studies found that abnormal FTO was related to oocyte maturation disorder [33]. A previous study has demonstrated that compared to the control group, the expression level of FTO in premature ovarian insufficiency (POI) patients and mouse models was significantly lower [33]. Knockdown of FTO in granulosa cells promoted cell apoptosis and inhibited proliferation [33]. These findings strongly suggested the potential role of FTO expression in ovarian function. However, little is known about whether MenSCs could restore the function of damaged ovaries by regulating the expression of FTO in granulosa cells. And we were also interested in the underlying molecular mechanism by which FTO affects the proliferation and apoptosis of granulosa cells.

To answer these questions, we designed an experimental methodology combining in vivo and in vitro models. They are POI mouse and coculture of injured granulosa cells with MenSCs, respectively. Our results showed that cisplatin-induced granulosa cell apoptosis via regulating the expression of FTO and MenSCs could restore the expression level of FTO. Furthermore, we identified that BNIP3 was a downstream target of FTO in mediating granulosa cell proliferation and apoptosis.

Materials and methods

Cell culture

Human ovarian granulosa cell lines KGN (Procell CL-0603) were kindly provided by Procell Life Science & Technology Co., Ltd (Wuhan, China). Cells were cultured in a T25 flask (Corning, New York, USA) containing DMEM/F12 (HyClone, Logan, UT) with 10% FBS (Sijiqing, China) in an incubator at 37°C with 5% CO2. The medium was changed every two days. When the cells reached 90% confluence, they were detached by 0.25% trypsin-EDTA and plated in a 6-well/96 well plate for the subsequent experiments, or passaged at a ratio of 1:3.

Isolation of menstrual-derived stem cells (MenSCs)

This study was approved in advanced by the Ethical Committee of The First Affiliated Hospital of Xi’an Jiaotong University, and all the participants have written an informed content. MenSCs were isolated and cultured as our previous study described [3]. Briefly, collecting the menstrual blood from 6 healthy women (about 25–30 years old), then transferring the blood into a 50 ml centrifuge tube, which pre-contained 10 ml of phosphate-buffered...
saline (PBS), 100 U/ml penicillin, 100 mg/ml streptomycin, amphotericin B (0.25 mg/ml), and ethylenediaminetetraacetic acid (EDTA) (2 mM) (Gibco, Grand Island, NY, USA). Ficoll-Paque Plus (GE Healthcare Amersham, UK) was used to separate and purify the MenSCs. Finally, cells were culture in DMEM/F12 (Hyclone, USA) with 10% fetal bovine serum (FBS) (Sijiqing, China), in a T25 flask (Corning, New York, USA) at 37 °C in 5% CO₂.

Establishing granulosa cell injury model and MenSCs-injured granulosa cells co-culture model

For the granulosa cell injury model, KGN was removed from the T25 flasks and seeded in a 96-well plate at a density of 1 × 10⁵. CDDP (Sigma–Aldrich, St. Louis, MO) was used to make the granulosa cell injury model. After overnight culture, removed the medium and replaced the fresh medium contained CDDP (0, 1, 5, 10, 15, 20 µM). Then the cells viability was measured by CCK-8 assay (Dojindo, Shanghai, China) at day 1, 2, and 3 according to the manufacturer’s instructions. Then the 50% inhibitory concentration (IC50) was chosen for the injury model in the later experiments.

For the MenSCs-injured granulosa cells co-culture model, we need to pre-seed the KGN (2 × 10⁵) in a 6-well plate and incubate for 24 h. Then, the CDDP was added for another 48 h. Finally, a 6-well transwell insert (6.5-mm polycarbonate membranes with pores 4.0 μm in size, Corning, USA) was applied. A total of 6 × 10⁵ MenSCs were resuspended in 500 µL complete culture medium and seeded in the upper chamber with 2 × 10⁵ injured granulosa cells resuspended in 1 ml complete culture medium in the lower chamber. After cells were cocultured for 48 h at 37°C in a 5% CO₂ incubator, the cells in the lower chamber were harvested (supplement).

Experimental animals, POF model establishment

To establish the POF models, C57BL/6 female mice, aged 6-8weeks, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. All experimental procedures were approved by the Ethical Committee and the Institutional Animal Care and Use Committee of Xi’an Jiaotong University. All animals were housed in a relatively stable environment with a cycle of lights on at 8 a.m. and off at 8 p.m., maintained room temperature (21–25 °C) with water and food available ad libitum. To establish the POF model, mice were injected with CDDP (2 mg/kg) intraperitoneally for 7 consecutive days, according to our previous study [3].

Experimental design

Experiment 1

To demonstrate the protective effects of MenSCs transplantation on POF ovarian function, the POF mice were divided into two groups and administered either treatment of MenSCs (passage 3–5, 200 µl cell suspensions containing 2 × 10⁶) by tail vein injection (MenSCs treated group, n = 15) or an equal volume of the medium (POF group, n = 15) on day eight. There are equal numbers of mice treated with 0.9% normal saline as a control group (n = 15). The animals were euthanized by cervical dislocation after 7 days of treatment. And the serum and ovaries were collected. We have recorded the bodyweight of each mouse every day.

Experiment 2

To explore the effects of FTO inhibitor MA [34] on POF ovarian function, the mice were randomly divided into 4 groups: (1) DMSO group (dimethyl sulfoxide, a solvent of MA, n = 15); (2) MA group (n = 15); (3) cisplatin group (n = 15); (4) cisplatin + MA group (n = 15). The POF models were established as mentioned earlier. The MA was administered simultaneously with cisplatin injection at the dose of 10 mg/kg. After 7 days of treatment, the animals were euthanized by cervical dislocation, and its ovaries were collected. During the experiment, we recorded the bodyweight of each mouse every day.

Enzyme Linked Immunosorbent Assay (Elisa)

Fourteen days after successful establishment of the model, the blood collected from the excised eyeball was transferred to a tube for centrifugation at 3000 r/min for 10 min at 4 °C, after which serum was obtained. Then, mice Elisa panel kits (Meimian Biotechnology, Jiangsu, China) were used to measure serum oestradiol (E2), FSH, and AMH levels according to the kit instructions. (Experiment 1)

Hematoxylin-eosin staining

The ovarian tissues were fixed in 4% paraformaldehyde for 24 h [35] and then embedded in paraffin, finally cut into a 5-µm serial section. Then the tissue sections were rehydrated by incubating in xylene and subjecting to an alcohol gradient of 100%–70%. After deparaffinization, the section was stained with hematoxylin and eosin (HE).

Immunohistochemistry

Immunohistochemistry (IHC) was performed as previously described [36]. The ovarian tissues of mice were fixed in 4% formaldehyde and paraffin-embedded using standard procedures. First, consecutive 4-µm sections were cut, deparaffinized with xylenes, rehydrated, and retrieved the antigen in sodium citrate solution (pH 6.0) for 20 min. Then the slides were treated with 3%
hydrogen peroxide to quench the endogenous peroxidase and blocked with 1% bovine serum albumin for 30 min to block the nonspecific binding. Next, tissue sections were incubated with primary antibody anti-FTO (Abcam, Cambridge, ab126605, USA; 1:150) overnight at 4 °C. Finally, wash the slides with PBS three times and incubate the slides with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:1000, Santa, Cruze) for another 30 min. Finally, a 3, 3-diaminobenzidine tetrahydrochloride (DAB) (Beyotime, Wuhan, China) substrate kit was applied to detect peroxidase reactivity. According to the manufacturer instructions, we prepared DAB peroxidase substrate in 5 ml ddH2O in a glass vial. Then, drop the DAB substrate on top of the slides and watch the brown staining. Dip slides into ice plus tap water to stop the reaction and rinse under cold tap water for 5 min.

**Plasmids and small interfering RNA transfection**

Overexpression and inhibition of FTO were achieved by transfection of pCAG-FTO (Miaoling, Wuhan, China) and FTO small interfering RNAs (siRNAs) (Ribobio, Guangzhou, China) separately. The empty vector for the plasmids and siRNAs were also included. The transient transfection of KGN was performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. In brief, a total of 2 x 10^5 cells per well were seeded into a 6-well plate. Until 60–80% confluence, 3.0 µg vector DNA or 50nM siRNA were transfected by 3.0 µL Lipofectamine 2000 per well for 6 h, then the medium was switched to fresh DMEM/F12. The overexpression and knockdown efficiency of the target gene was measured by qRT-PCR and western blotting.

**Western blotting analysis**

Cells were harvested after 48 h incubation. The total protein was extracted by RIPA buffer, which was pre-added with protease inhibitor cocktail and PMSF. BCA kit (Beyotime, China) was used to determine the protein concentration. 30 µg of protein was subjected to 10% SDS-PAGE gels and then transferred polyvinylidene difluoride (PVDF) membrane. The membranes were blocked in 0.1% TBST (Tris – HCl buffer saline with 0.1% Tween – 20) contained 5% skimmed milk. Then, these membranes were incubated with corresponding primary antibodies in 4°C overnight. The primary antibodies are as follows: FTO (1:1000, ab126605 Abcam, USA), BNP3 (1:1000, ab109362 Abcam, USA), BAX (1:1000, 50599-2-lg, Proteintech, China), Bcl-2(1:1000, 12789-1-AP, Proteintech, China), β-actin(1:1000, 66099-1-lg, Proteintech, China). The next day, these membranes were incubated with peroxidase - conjugated secondary antibodies at room temperature for 1 h. Finally, these membranes were visualized by enhanced chemiluminescence (ECL) procedure.

**RNA extraction and quantitative real-time PCR (qRT-PCR)**

Total RNA from cells was isolated using RNAiso Plus (Takara, Japan) according to the reagent instruction. Gene primers used in this study were as follows:

**FTO** (forward, 5’ – TTCACCAAGGAGACTGCTAT TCC – 3’, reverse, 5’ – CAAGGTTCTCTGGAGCA CTCCTG – 3’),

METTL3 (forward, 5’ – TTTGTCCTCAAACCTCTCGT AGT – 3’, reverse, 5’ – CCAGATCAGAGGTTGGT GTAG – 3’), METTL14 (forward, 5’ – ACCCTTGAAA GAGTTGGTTACGA – 3’, reverse, 5’ – TGTGAGCCA GCCTTGTCTC – 3’),

WTAP (forward, 5’–TGTGCTGTGTAAGGGGCTAT CTCGACTCATGC–3’reverses5’–ACTGGGCAAACT TGGCAGTCATAAACCCAC–3’),

ZC3H13 (5’ – AAGAGGGTTTTACCCAGAAGTG – 3’, reverse, 5’ – CGCTTCCGAGATTGTGACAG – 3’),

KIAA1429 (5’ – AAGTGCCCCTGTGTTCTAGATAG – 3’, reverse, 5’ – ACCAGACCATCTAGATTCCTCACT – 3’),

RBM15 (5’ – AGCGCGCACTGTAGTACCC – 3’, reverse, 5’ – GCCCGGAGAATTTCGTTGCTC – 3’),

YTHDF1 (forward, 5’ – AACAAAGGGGGAACCA GT – 3’, reverse, 5’ – GACACACTGGAGCTGACCA – 3’),

YTHDF2 (forward, 5’– TAGCCCACTCGCAGACCAT TC – 3’, reverse, 5’ – CACGACCTTGAGCTTCTT – 3’),

YTHDF3 (forward, 5’ – TGACAAACAAACCGGT TACCA – 3’, reverse, 5’ – TGGTTCTATTTTCTCTCCC TACGC – 3’),

YTHDC1 (forward, 5’ – TCATCTTCCGTTCGTGCT GT – 3’, reverse, 5’ – TACAAGGAGGCTGGGACCATA – 3’),

GAPDH (forward, 5’ – AAAATCAAGTGGGGCGGAT GCT – 3’, reverse, 5’ – TGGTTCACCCCATGACG AAC),

BNP3 (forward, 5’ – TGAAGTCTGGAGAGGATG CTC – 3’, reverse, 5’ – CCGTGTGATATTCTGTG GTGT – 3’),

BAX (forward, 5’ – AGTAGCCAGCTGACAGTTTT – 3’, reverse, 5’ – GGGAGCATTCCAAATGGCCAG – 3’),

Bcl-2 (forward, 5’ – TTCACAGGCGGAGGACG – 3’, reverse, 5’ – GGACATTGCTGGCGGCCCTGAT – 3’),

Real-time quantitative PCR was performed using SYBR Premix Ex Taq™ (Takara) on a StepOne Real – Time PCR System (7300 Real – Time PCR system, Applied Biosystems, USA). The reaction conditions were as follows: 95 °C for 30s, 40 cycles at 95 °C for 15s, 60 °C for 30s, and extension at 72 °C for 60s. The target genes relative expression levels were analyzed by the 2 –ΔΔCt method.
Cell counting kit-8 (cck-8) assay
The cell proliferation was determined by using the Cell Counting Kit-8 (CCK8) assay [37]. In brief, 1 × 10^4 KGN cells per well were plated into a 96-well plate. Then, cells were cultured at 37 °C with 5% CO₂ for 24 h. After the different treatments, 10 ul of CCK8 reagent (Dojindo, Kumamoto, Japan) and 90ul culture medium were added per well and incubated at 37 °C for 2 h. Finally, measured the absorbance at 450 nm at 24 h, 48 h, and 72 h.

EdU labeling
To assess the KGN proliferation, 5-ethynyl-2-deoxyuridine (EdU) Apollo567 kit (Ribobio Co., Ltd.) was used. First, KGN (1 × 10^4) were cultured in a 96-well plate and incubated with EdU (1:1000, 50 µmol/L) for 2 h. Then, KGN was fixed with 4% formaldehyde for 30 min at room temperature, followed by incubation with glycine (2 mg/ml) and PBS for 5 min respectively. Next, permeabilized the cells in 0.5% Triton X-100 (100 µL) for 10 min and added the Apollo® reaction cocktail (100 µL) for 30 min under light-shading conditions at room temperature. Finally, 4′,6′-diamidino-2-phenylindole (DAPI) was used to counterstain the nuclei for 30 min at room temperature. After 3 times washes with PBS, the images were acquired using fluorescent microscopy (Olympus, Japan).

Flow cytometry analysis
Annexin V – FITC Apoptosis Detection Kit (BD Biosciences, CA, USA) was used to assess the KGN cell apoptosis. Briefly, KGN was harvested and washed in ice-cold PBS. Then, resuspended the cells in binding buffer (200 µL) and added the Annexin V – FITC (5 µL) and propidium iodide (5 µL) in it at room temperature for 10 min (in darkness). Finally, added 300 µL binding buffer to each tube and the percentage of apoptotic KGN cells were analyzed using flow cytometer (FC 500, MCL, CA).

Statistical analysis
All cell experiments were carried out in triplicate. The data were represented as mean±SEM and statistical analysis was conducted with GraphPad Prism 5. Student’s t-test and one-way ANOVA were applied to compare the two experimental groups and multiple groups, respectively. And the data was analyzed with the observer blind to the treatment. P value <0.05 was considered statistically significant.

Results
Effects of cisplatin on KGN cell proliferation and apoptosis
To evaluate the effect of cisplatin on KGN cell viability, a CCK-8 assay was conducted. The results showed that cisplatin (0–20 µM) induced cell death in a dose-dependent and time-dependent fashion (Fig. 1A), and the 50% inhibitory concentration (IC50) (half-maximal inhibitory concentration) was obtained by treating cells with 10 µM cisplatin for 48 h. Then, we detected the mRNA and protein expression levels of BAX and Bcl-2 and found that when the concentration of cisplatin was lower than 10 µM, as the concentration of cisplatin increased, the apoptotic ability of cells gradually increased, while the anti-apoptotic ability gradually weakened. When the cisplatin concentration was higher than 10 µM, the opposite result was obtained (Fig. 1B-F). We speculate that when the concentration of cisplatin is more than 10 µm, the remaining cells produce a self-protective ability to resist cisplatin injury, resulting in the enhancement of their anti-apoptosis ability. We cannot exclude the possible existence of other mechanisms that explain this resistance to cisplatin injury. Finally, we used the KGN cell culture with cisplatin 10 µM for 48 h as the granulosa cell injury model.

Treatment with MenSCs or conditioned medium improved injured granulosa cell function
To examine the effect of MenSCs on injured granulosa cells, a coculture model was used to mimic the MenSCs-injured granulosa interplay in vitro. Compared with the cisplatin treatment alone, the anti-apoptotic ability of MenSCs cocultured injured granulosa cells was enhanced. As shown in (Fig. 2A-E), the mRNA and protein expression levels of Bcl-2 improved, while those of BAX decreased. Conditioned medium was collected from MenSCs. When MenSCs reached 80% confluence, the medium was switched to serum-free medium, and the cells were cultured for another 48 h. The CCK-8 assay showed that the conditioned medium could promote the injured granulosa cell viability (Fig. 2F). These results demonstrated that MenSCs promoted cisplatin-induced injured granulosa cell proliferation and decreased apoptosis.

MenSCs transplantation increased weight and improved injured ovarian function
As we described previously, the following evaluation indices were used to assess whether MenSCs transplantation could improve the ovarian dysfunction caused by cisplatin: weight, number of follicles, and serum sex hormone [3]. As shown in Fig. 3D, body weight increased significantly in the MenSCs transplantation group compared with the POF group. Furthermore, compared with the POF group, the levels of E2 and AMH were higher, while the level of FSH was lower in MenSCs group (Fig. 3E-G). The follicle numbers were increased significantly in the MenSCs transplantation groups compared with the POF.
These results demonstrated treatment with MenSCs improved ovarian function of POF mice.

MenSCs restored the expression of FTO in injured granulosa cells and POF mice
We analyzed the expression levels of m6A-related elements and found that compared those in the cisplatin group, the mRNA expression levels of METTL3, METTL14, WTAP, ZC3H13, KIAA1429, RBM15, ALKBH5, YTHDF1, YTHDF2, YTHDF3, and YTHDC1 were all decreased in the MenSCs coculture model group, while the expression of FTO was increased (Fig. 3A). The protein expression level of FTO was also detected (Fig. 3B-C). We further detected the expression levels of FTO in animal models and found that in the POF group, the FTO expression was decreased, and the MenSCs transplantation reversed this decrease (Fig. 3I). These findings suggest that identification of FTO may explain, at least in part, the mechanisms of MenSCs improving the POF ovarian function.

Overexpression of FTO reversed the effects of cisplatin on granulosa cells proliferation and apoptosis
First, to explore the effect of FTO on granulosa cells viability, FTO was transiently transfected into granulosa cells, resulting in increased protein and transcript levels of FTO compared to those transfected with negative controls (NC) (Fig. 4A). CCK-8 and EdU assays showed that overexpression of FTO resulted in a significant increase in cell proliferation rate (Fig. 4LM). qRT-PCR (Fig. 4B-C), western blotting (Fig. 4D-G), and flow cytometry – V/PE (Fig. 4N-O) staining showed that FTO could decrease granulosa cells apoptosis, resulting in a decrease in the expression level of BAX and an increased in the expression level of Bcl-2.

Then, we further investigated the effect of FTO on injured granulosa cells. Compared to the cisplatin-treated group, ectopic expression of FTO resulted in its up-regulation and restored the cisplatin-induced down-regulation of FTO in granulosa cells (Fig. 4H-K). In addition, CCK-8 and EdU assays showed that restoration of FTO expression prevented granulosa cells from decreasing the proliferation induced by cisplatin treatment (Fig. 4L-M). The rate of cell apoptosis was also tested, and the results showed that restoration of FTO decreased cell apoptosis. The expression levels of BAX and Bcl-2 also returned to the level of the NC (Fig. 4N-O). These results indicated that FTO is protective in cisplatin-induced damage.
Down-regulation of FTO aggravates cisplatin-induced apoptosis

The effects of FTO knockdown on granulosa cell viability were also examined in this study. Transfection efficiency was confirmed by qRT-PCR. The mRNA level of FTO substantially decreased in the si-FTO group compared to the si-NC group (Fig. 5A). After 48 h of transfection with si-FTO, the cell proliferation rate was detected by CCK-8 and EdU assays. As shown in (Fig. 5L-M), the proliferation rate decreased significantly in the si-FTO group. Simultaneously, flow cytometry-V/PE staining showed that silencing of FTO in granulosa cells promoted cell apoptosis (Fig. 5N-O). FTO, BAX, and Bcl-2 expression levels were also detected by both qRT-PCR and western blotting. The expression of FTO and Bcl-2 decreased significantly in the si-FTO group, while the expression of BAX increased (Fig. 5A-G).

Furthermore, we investigated the effect of si-FTO on injured granulosa cells. The protein expression levels of FTO and Bcl-2 were lower and the expression level of BAX was higher in the si-FTO and cisplatin cotreated group compared to those in cisplatin-treated only group (Fig. 5H-K). The CCK-8, EdU, and flow cytometry-V/PE staining assays showed the same results (Fig. 5L-O). These results demonstrated that down-regulation of FTO aggravated the apoptosis of injured granulosa cells.
Fig. 3  MenSCs restored the expression of FTO in injured granulosa cells and POF mice. A-C qRT-PCR and western blotting results showed that FTO expression was decreased in injured granulosa cells, and MenSCs co-culture could restore it. The results represent the mean ± SEM from three independent experiments. D-G POF mice models and MenSCs transplantation were established, and changes in the body weight, serum levels of E2, FSH, and AMH in different groups were shown. The graphs show the mean ± SEM (n = 15 mice per group). H & E staining showed the morphological, follicle numbers, and histopathological change of the ovary after different treatments. I IHC results showed the FTO expression was decreased in the POF group compared to the controls, while MenSCs transplantation could restore it. (n = 15 mice per group). Scale bars in the HE staining represents 8 × 200 μm, while in the IHC staining represents 15 × 200 μm. Student’s t test. (*P < 0.05, **P < 0.01, ***P < 0.001)

Fig. 4  Overexpression of FTO attenuated cisplatin-induced granulosa cell apoptosis and promoted its proliferation. A The transfection efficiency of FTO was measured by qRT-PCR. B-C The mRNA expression of Bcl-2 and BAX in transfected granulosa cells was assessed using qRT-PCR and normalized to GAPDH. D-G The protein expression of FTO, BAX, and Bcl-2 was determined by western blotting with β-actin as a loading control in different groups. (H-K) Western blotting results showed that overexpression of FTO in injured granulosa cells could restore the cisplatin-induced change of FTO, Bcl-2, and BAX. L-M Edu labeling and cck-8 assay indicated that cells viability was inhibited in cisplatin-induced injured cells. However, transfection of FTO in injured cells, the viability was increased. N-O Flow cytometry assays were performed to determine the apoptotic rate in different groups. The results showed that cell apoptotic rate was increased in the cisplatin-induced injured cell, while co-transfection of FTO could restore it. One representative experiment of three independent experiments is shown. The results represent the mean ± SEM from three independent experiments. Student’s t-test and one-way ANOVA were applied to compare the two experimental and multiple groups, respectively. (*P < 0.05, **P < 0.01, ***P < 0.001, ns, no significance)
Fig. 4 (See legend on previous page.)
FTO promoted granulosa cells proliferation and attenuated apoptosis may be by targeting BNIP3

To verify BNIP3 as a downstream target of FTO, BNIP3 mRNA and protein expression levels were detected in granulosa cells. Compared to the NC group, overexpression of FTO decreased both the mRNA and protein levels of BNIP3 in normal granulosa cells (Fig. 6A-B). Furthermore, in the injured granulosa cells, we found that up-regulation of FTO reversed the changes in expression levels of BNIP3 induced by cisplatin to those of the NC group (Fig. 6B-C). However, down-regulation of FTO obtained the opposite results (Fig. 6E-G). These results demonstrated FTO considerably decreased BNIP3 expression at transcriptional and translation levels in granulosa cells. And downregulation of BNIP3 was involved in the FTO overexpression-induced proliferation of granulosa cells.

An inhibitor of FTO (MA) promoted cisplatin-induced cytotoxicity in granulosa cells

Granulosa cells were treated with different concentrations of MA (0, 20, 25, 30, 35, 40, 45, 50, 55, 60 µM) for 48 h to determine the optimum treatment concentration of MA. Based on the results of CCK-8 assay, we chose 30 µM as the MA concentration for the subsequent experiments, which was the highest dose that showed no significant effect on cell death (Fig. 7A).

The cells and animals were divided into 4 groups, including the control group, MA-treated group, cisplatin-treated group, and cisplatin + MA-treated group, to explore the effect of MA on the cisplatin-induced injury. The results showed that compared to the control group and MA group, the cisplatin-treated group, and cisplatin + MA-treated group had significantly decreased cell proliferation rates (Fig. 7B). Furthermore, the cisplatin + MA treatment group showed aggravated the cell injury compared to the cisplatin-treated group (Fig. 7C-G). H & E staining showed that MA promoted the cisplatin-induced injury in the ovary (Fig. 7H). In the cisplatin + MA-treated group, the follicle numbers were significantly lower than cisplatin-treated alone. These results suggested that MA significantly increased cisplatin-induced granulosa cells apoptosis and ovarian damage.

Discussion

POF is a serious complication of chemotherapy, and its incidence reaches 1/1000 in women under 30 years old, 1/250 in women under the age of 35 years old, and 1/100 in women under the age of 40 years old [38, 39]. Nowadays, the main treatment for POF is hormone replacement therapy [3]. However, it fails to resolve the fundamental problem, such as ovarian reserve and fertility restoration. Other strategies for female fertility preservation in the face of chemotherapy include embryo, oocyte, and ovarian tissue cryopreservation [40]. But transplantation of ovarian tissues may carry additional risks of reintroducing cancer cells [41]. Therefore, it's urgent to explore other treatments that can prevent ovarian damage induced by chemotherapy. Previous studies have demonstrated that MenSCs can restore ovarian function and decrease the granulosa cell apoptosis induced by chemotherapy agents [3, 14, 16, 42]; however, the regulatory mechanisms are still unknown. In this study, we first established a granulosa-injured cell model and MenSCs-injured granulosa coculture model and found that MenSCs could decrease granulosa cell apoptosis induced by cisplatin and that conditioned medium from MenSCs could promote injured granulosa cell proliferation. A previous study demonstrated that overexpression of FTO could decrease the cisplatin-induced cell apoptosis in acute kidney injury [43], and in POI patients and mouse models, the expression level of FTO decreased significantly compared with that in the control groups [33, 44]. Therefore, we wondered whether MenSCs promote injured granulosa cell proliferation and decrease apoptosis through up-regulation of FTO. The results showed that compared to the control group, FTO expression decreased in the cisplatin treatment group, while in the MenSCs-injured granulosa coculture group, the expression level of FTO increased. In addition, we established a POF mouse model and MenSCs transplantation, and the IHC results showed that the FTO expression decreased in the POF group and increased in the...
Fig. 5 (See legend on previous page.)
MenSCs transplantation group. These findings strongly suggested that FTO plays a vital role in recovering ovarian function.

To better understand the role of FTO in granulosa cell viability, gain- and loss-of-function studies were employed. The flow cytometry assay revealed that ectopic expression of FTO could attenuate cisplatin-induced apoptosis. CCK-8 and EdU assays showed that restoration of FTO expression prevented granulosa cells from cisplatin-mediated changes in cell proliferation. Knockdown of FTO by pharmacological (MA) or genetic (siRNA) constructs promoted cisplatin-induced apoptosis in granulosa cells. These findings suggested that cisplatin-induced granulosa cell apoptosis in an FTO-dependent manner.

At the molecular level, there are two pathways involved in granulosa cell apoptosis; death receptor and mitochondrial pathways [45]. In the mitochondrial pathways, the pro-apoptotic protein BAX can initiate apoptosis and accelerate follicular atresia [46], while Bcl-2 can act antagonistically on BAX and prevent cell apoptosis [47]. Then, we detected the expression levels of BAX and Bcl-2. qRT-PCR and western blotting showed that in the cisplatin treatment group, the expression level of Bax increased, while Bcl-2 expression decreased. Overexpression of FTO in the cisplatin group restored Bax and Bcl-2 to the levels observed in the NC group. However, downregulation of FTO in the cisplatin group promoted the Bax expression and decreased Bcl-2 expression. In summary, molecular and functional analyses confirmed that FTO plays a positive role in cisplatin-induced cell injury.

We further explored the downstream working mechanism of FTO. BNIP3, a member of the Bcl-2 family [48], is a target of FTO in breast cancer that mediates cell proliferation and apoptosis [49]. A previous study has demonstrated that BNIP3 was involved in the cisplatin-induced cell apoptosis [50]. We wondered whether BNIP3 acts as a target of FTO to participate in cisplatin-induced granulosa cell apoptosis. In our study, overexpression of FTO decreased BNIP3 expression at both the mRNA and protein levels. In addition, silencing FTO expression in injured granulosa cells produced the opposite results.

![Fig. 6 Overexpression of FTO attenuated injured granulosa cells' apoptosis by downregulating the expression of BNIP3. A. Compared to the NC group, the BNIP3 mRNA level was decreased in the FTO group. B. The western blotting result showed that overexpression of FTO could reverse the expression level of BNIP3 induced by cisplatin. C. qRT-PCR showed that downregulation of FTO increased the expression level of BNIP3. D. The western blotting showed that downregulation of FTO promoted the expression level of BNIP3 induced by cisplatin. β-actin served as the loading control. One representative experiment of three independent experiments is shown. The results represent the mean ± SEM from three independent experiments. Student’s t-test and one-way ANOVA were applied to compare the two experimental and multiple groups, respectively. (*P < 0.05, **P < 0.01, ***P < 0.001, ns, no significance).](image-url)
Fig. 7 MA promoted cisplatin-induced cytotoxicity in granulosa cells, and cisplatin-induced injury in the ovary. A granulosa cells were incubated with different concentrations of MA for 48 h, the cell viability was measured by cck-8 assay. B granulosa cells were incubated with selected cisplatin in the presence or absence of MA for 48 h, and the cell viability was measured by cck-8 assay. C-G The western blotting showed that MA increased the cisplatin-induced BAX and BNIP3 expression and decreased the cisplatin-induced FTO and Bcl-2 expression. One representative experiment of three independent experiments is shown. The results represent the mean ± SEM from three independent experiments. one-way ANOVA was used to compare the multiple groups. H HE staining suggested MA promoted cisplatin-induced injury in the ovary. (n = 15 mice per group). (*P < 0.05, **P < 0.01, ***P < 0.001, ns, no significance)
Previous studies have demonstrated that autophagy is involved in cisplatin-induced apoptosis in various cancers, such as pancreatic cancer [51] and lung cancer [52]. In hair cell-like HEI-OC1 cells, downregulation of FTO reduced reactive oxygen species (ROS) accumulation, inhibited apoptosis and the cisplatin-induced excessive autophagy, and protected and improved the viability of HEI-OC1 cells [7]. BNIP3, a downstream target of FTO [49], can act as an autophagy-related protein [53] and interact with LC-3 through the LC-3-interacting region to promote autophagy [54]. For example, in ovarian cancer cells, cisplatin-induced cellular autophagy was dependent on BNIP3 [50], and in the lung cancer cells, hypoxia augmented cisplatin-induced autophagy by suppressing the BNIP3 death pathway [55]. We speculated that in POF, overexpression of FTO inhibited cisplatin-induced granulosa cell apoptosis through BNIP3-mediated autophagy. We will explore this issue in our future studies.

There are many limitations to this study. Admittedly, our results would be more convincing if the expression of FTO was examined in ovary samples of POF patients and normal donors. However, we had no access to ovarian samples due to limitations in clinical treatment and ethics requirements. A previous study has reported that cisplatin-induced injured granulosa cells could promote bone marrow-derived mesenchymal stem cells (BMSCs) migration. BMSCs reduced injured cell apoptosis both in vivo and in vitro. However, in vivo, the migrated BMSCs did not locate in the follicles and corpus lutea [10]. We hypothesize that some factors must be secreted from the stem cells to protect injured granulosa cells. In this study, when the MenSCs were cocultured with injured granulosa cells, cell apoptosis decreased. Furthermore, we found that the expression of FTO increased in the injured cells. However, which factors secreted from the MenSCs promote the FTO expression is still unknown.

Conclusions
In summary, our studies showed that MenSCs increase the expression of FTO to attenuate the cisplatin-induced granulosa cell apoptosis. The upregulation of FTO in granulosa cells decreased cisplatin-induced apoptosis by inhibiting the expression of BNIP3. Inhibition of FTO can further increase granulosa cell apoptosis induced by cisplatin. FTO may play a protective role in cisplatin-induced injured granulosa cell apoptosis.

Abbreviations
POF: Premature ovarian failure; m6A: RNA methylation on the sixth Natom of adenylate; FTO: fat mass- and obesity-associated; MenSCs: menstrual-derived stem cells; MA: meclofenamic acid; CDDP: Cis-diamminedichloroplatinum-II;
References

1. Laven JSE. Primary Ovarian Insufficiency. Semin Reprod Med, 2016(34):230–234.
2. Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017(62):51–6.
3. Wang Z, Wang Y, Yang T, et al. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther. 2017;8(1):11.
4. Jang H, Na Y, Hong K, et al. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27(Kip1) promoter in primordial follicles. J Pineal Res. 2017;63(3).
5. Laurell G, Beskow C, Frankendal B, et al. Cisplatin administration to gynecologic cancer patients. Long-term effects on hearing. Cancer. 1996;78(8):796–804.
6. Merouani A, Davidson SA, Schrier RW. Increased Nephrotoxicity of Combination Taxol and Cisplatin Chemotherapy in Gynecologic Cancers as Compared to Cisplatin Alone. Am J Nephrol. 1997;17(1):53–8.
7. Li H, Song Y, He Z, et al. Melatonin reduces reactive oxygen species accumulation and apoptosis, inhibits excessive autophagy, and protects hair cell-like HEI-OC1 cells from cisplatin-induced damage. Front Cell Neurosci. 2018;12:139.
8. Sklar CA, Mertens AC, Mibty P, et al. Premature Menopause in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. JNCI. J Natl Cancer Inst. 2006;98(13):890–6.
9. Morse H, Elfving M, Lindgren A, et al. Acute onset of ovarian dysfunction in women after start of cancer treatment. Pediatr Blood Cancer. 2013;60(4):676–81.
10. Liu J, Zhang H, Zhang Y, et al. Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats. Mol Cells. 2014;37(12):865–72.
11. Bildik G, Esmaeilian Y, Yatanserver D, et al. A comparative molecular analysis of DNA damage response, cell cycle progression, viability and apoptosis of malignant granulosa cells exposed to gemcitabine and cisplatin. Mol Biol Rep. 2020;47(5):3789–96.
12. Atesjahnin A, Şahna E, Türk G, et al. Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. J Pineal Res. 2006;41(1):1–7.
13. Jang H, Lee OH, Lee Y, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/PI3K/AKT/FOXO3a pathway activation in the mouse ovary. J Pineal Res. 2016;60(3):336–47.
14. Feng P, J.P, Tan J. Human Menstrual Blood-Derived Stromal Cells Promote Recovery of Premature Ovarian Insufficiency via Regulating the ECM-Dependent FAK/AKT Signaling. Stem Cell Rev. Rep. 2019;15(2):241–55.
15. Yoon SY, Yoon JA, Park M, et al. Recovery of ovarian function by human embryonic stem cell-derived mesenchymal stem cells in cisplatin-induced premature ovarian failure in mice. Stem Cell Res Ther. 2020;11(1):255.
16. Manshadi MD, Navid S, Hoshino Y, et al. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure. Micros Res Tech. 2019;82(6):635–42.
17. Zhang H, Luo Q, Lu X, et al. Effects of HPV56S on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice. Stem Cell Res Ther. 2018;9(1):20.
18. Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Res Ther. 2019;10(1):46.
19. Yan Z, Guo F, Yuan Q, et al. Endometrial mesenchymal stem cells isolated from menstrual blood repaired eripurcin-induced damage to human ovarian granulosa cells by inhibiting the expression of Gadd45b in cell cycle pathway. Stem Cell Res Ther. 2019;10(1):4.
20. Zafarouds S, Kazemnejad S, Darzi M, et al. Improvement of Pregnancy Rate and Live Birth Rate in Poor Ovarian Responders by Intravenous Administration of Autologous Menstrual Blood-Derived–Mesenchymal Stromal Cells: Phase II/III Clinical Trial. Stem Cell Rev Rep. 2020;16(4):755–63.
21. Panneerdoss S, Eedunuri VK, Yadav P, et al. Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression. Sci Adv. 2018;4(10):eaat263.
22. Ivanova I, Much C, Di Giacomo M, et al. The RNA m(6)A Reader YTHDF2 Is Essential for the Post-transcriptional Regulation of the Maternal Transplantome and Oocyte Competence. Mol Cell. 2017;67(6):1059–67.
23. Zhang B, Jiang H, Dong Z, et al. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases. Genes Dis. 2021;8(6):746–58.
24. He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.
25. Chen Y, Lin Y, Shu Y, et al. Interaction between N(6)(methyladenosine) (m(6)A) modification and noncoding RNAs in cancer. Mol Cancer. 2019;18(1):94.
26. Hu Y, Ouyang Z, Sui X, et al. Cisplatin resistance is maintained by m 6 A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nat Commun. 2019;10(1):2065.
27. Hu P, Zhu Y, Ma H, et al. YTHdc2 is an N6-methyladenosine binding protein that regulates mammalian spermogenesis. Cell Res. 2017;27(9):115–27.
28. Boissel S, Reish O, Proulx K, et al. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet. 2009;85(1):106–17.
29. Qi ST, Ma JY, Wang ZB, et al. N6-Methyladenosine Sequencing Highlights the Involvement of mRNA Methylation in Oocyte Meiotic Maturation and Embryo Development by Regulating Translation in Xenopus laevis. J Biol Chem. 2016;291(44):23200–20.
30. Ding C, Zou Q, Ding J, et al. Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018;233(9):7055–66.
31. Huang Y, Yan J, Li Q, et al. N6-methyladenosine selectivity inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2013;41(1):373–84.
32. Huang J, Zeng F, Xu Q, et al. Cryptotanshinone decreases granulosa cell apoptosis and restores ovarian function in mice with premature ovarian failure. Gen Physiol Biophys. 2020;39(3):277–83.
33. Wang R, Zou L. Downregulation of LncRNA-MEG3 promotes HTB/H/shm cells apoptosis and attenuates its migration by repressing Notch1 signal in preeclampsia. Reproduction. 2020;160(1):21–9.
34. Gilbert DF. Cell Viability Assays: Methods and Protocols. Methods in Molecular Biology; 2017.
35. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604–6.
36. Nelson LM. Clinical practice. Primary ovarian insufficiency: N Engl J Med. 2009;360(6):606–14.
37. Roness H, Kashfi O, Merovod D. Prevention of chemotherapy-induced ovarian damage. Fertil Steril. 2016;105(1):20–9.
38. Dolmans MM, Luyckx V, Donnez J, et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99(6):1514–22.
39. Liu T, Huang Y, Zhang J, et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. Stem Cells Dev. 2014;23(13):1548–57.
40. Zhou P, Wu M, Ye C, et al. M6Cacnoic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m 6 A aberration in RNA. J Biol Chem. 2019;294(45):16908–17.
41. Huang B, Ding C, Zou Q, et al. Cyclophosphamide Regulates N6-Methyladenosine and m6A RNA Enzyme Levels in Human Granulosa Cells and in Ovaries of a Premature Ovarian Aging Mouse Model. Front Endocrinol (Lausanne). 2019;10:415.
and Mcl-1. Proceedings of the National Academy of Sciences - PNAS, 2011;108(32):13135–13140.

48. Reed JC. Bcl-2 family proteins. Oncogene. 1998;17:3225–36.

49. Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18(1):46.

50. Jia J, Yang X, Zhao Q, et al. BNIP3 contributes to cisplatin-induced apoptosis in ovarian cancer cells. FEBS open bio. 2020;10(8):1463–73.

51. Kong F, Liu X, Zhou Y, et al. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol. 2020;122:105731.

52. Shi S, Tan P, Yan B, et al. ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells. Oncol Rep. 2016;35(5):2606–14.

53. Jawhari S, Ratinaud MH, Verdier M. Glioblastoma, hypoxia and autophagy: a survival-prone ‘menage-a-trois’. Cell Death Dis. 2016;7(10):e2434.

54. Drake LE, Springer MZ, Poole LP, et al. Expanding perspectives on the significance of mitophagy in cancer. Sem Cancer Biol. 2017;47:110–24.

55. Wu H, Jiang Z, Ding P, et al. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep. 2015;5(1):12291.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions